Dr. Andy I. Chen, MD, PHD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 131
Licensed in California since 2002, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OR license MD29381 -
Hematology & Oncology Physician
CA license A79757 (first issued 2002; current) · OR license MD29381
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
- Salem Hospital Salem, OR
- Hillsboro Medical Center Hillsboro, OR
Medical groups
- University Professional Services (1,724 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 131
- Services billed
- 677
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 214 | 49 |
| Established patient office or other outpatient visit, 40-54 minutes | 89 | 37 |
| Established patient office or other outpatient visit, 30-39 minutes | 55 | 32 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 28 | 26 |
| Hospital discharge day management, more than 30 minutes | 20 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Portland, OR | 119 |
| Prochlorperazine Maleate Other prescribers in Portland, OR | 26 |
| Allopurinol Other prescribers in Portland, OR | 23 |
| Brukinsa (zanubrutinib) | 17 |
| Ondansetron Odt (ondansetron) Other prescribers in Portland, OR | 17 |
| Dexamethasone Other prescribers in Portland, OR | 13 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Portland, OR | 13 |
| Fluconazole Other prescribers in Portland, OR | 11 |
| Potassium Chloride Other prescribers in Portland, OR | 11 |
| Prednisone Other prescribers in Portland, OR | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $32.74 in total to this clinician.
| Beone Medicines USA, Inc. | $32.74 |
|---|
| Food and Beverage | $32.74 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $93,083 in research payments for these studies, mostly to the institutions running them.
- Phase II, Open Label, Study of PHE885, a B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma
Novartis Pharmaceuticals Corporation - A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated…
AstraZeneca UK Limited - Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Kite Pharma, Inc. - Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel
Kite Pharma, Inc. - A Phase II single arm multicenter open label trial to determine the efficacy and safety of CTL019 in adult patients with refractory or relapsed follicular lymphoma
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.